English
SpanishTrusted Resources: Education
Scientific literature and patient education texts
Combination Therapy With Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I
source: Journal of clinical medicine
year: 2021
authors: Mirea A,Shelby ES,Axente M,Badina M,Padure L,Leanca M,Dima V,Sporea C
summary/abstract:Spinal muscular atrophy (SMA) is a neuromuscular progressive disease, characterized by decreased amounts of survival motor neuron (SMN) protein, due to an autosomal recessive genetic defect. Despite recent research, there is still no cure. Nusinersen, an antisense oligonucleotide acting on the gene, is intrathecally administered all life long, while onasemnogene abeparvovec-xioi, a gene therapy, is administered intravenously only once. Both therapies have proven efficacy, with best outcomes obtained when administered presymptomatically. In recent years, disease-modifying therapies such as nusinersen and onasemnogene abeparvovec-xioi have changed the natural history of SMA.
organization: Faculty of Midwifery and Nursing, University of Medicine and Pharmacy "Carol Davila", 37 Dionisie Lupu Street, 020021 Bucharest, Romania.DOI: 10.3390/jcm10235540
read more
BookmarkRelated Content
-
Expert Recommendations and Clinical Considerations in the Use of Onasemnogene Abeparvovec Gene Therapy for Spinal Mu...Spinal muscular atrophy (SMA) is an auto...
-
Patient of the Month: GiannaAfter noticing that her daughter was una...
-
Infants With Symptomatic SMA Reach Milestones With Gene TherapyGene replacement therapy with onasemnoge...
-
Your Guide to Spinal Muscular Atrophyhttps://simedhealth.com/sites/default/fi...
-
Pediatric Spinal Muscular AtrophyWhat is spinal muscular atrophy (SMA)?Sp...
-
Recombinant Adeno-Associated Virus Serotype 9 Gene Therapy in Spinal Muscular AtrophySpinal muscular atrophy (SMA) is an auto...
-
A Caregiver’s Guide to ZolgensmaIndication ZOLGENSMA® (onasemnogene abe...
Powered by
In partnership with
